Profile data is unavailable for this security.
About the company
Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.
- Revenue in INR (TTM)214.84bn
- Net income in INR42.78bn
- Incorporated1995
- Employees26.24k
- LocationZydus Lifesciences LtdZydue Tower, Satellite Cross RoadAHMEDABAD 382481IndiaIND
- Phone+91 7 926868100
- Fax+91 7 926862365
- Websitehttps://www.zyduslife.com/zyduslife/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbott India Ltd | 60.66bn | 12.85bn | 607.68bn | 3.81k | 47.30 | 17.26 | 44.79 | 10.02 | 604.57 | 604.57 | 2,854.72 | 1,657.05 | 1.27 | 5.32 | 15.71 | 15,904,690.00 | 26.82 | 20.92 | 36.97 | 28.59 | 45.09 | 44.20 | 21.18 | 17.26 | 1.71 | 131.36 | 0.0169 | 77.06 | 9.35 | 9.72 | 26.52 | 21.68 | 31.08 | 52.32 |
| Alkem Laboratories Ltd | 127.32bn | 20.54bn | 658.01bn | 17.28k | 32.03 | -- | 27.63 | 5.17 | 171.81 | 171.81 | 1,064.87 | -- | -- | -- | -- | 7,369,150.00 | -- | 11.88 | -- | 17.50 | 62.21 | 59.26 | 16.29 | 13.94 | -- | 9.12 | -- | 29.82 | 9.21 | 11.48 | 82.47 | 18.75 | -13.30 | 20.11 |
| Aurobindo Pharma Ltd | 302.95bn | 35.82bn | 736.11bn | 8.80k | 20.68 | 2.38 | 14.39 | 2.43 | 61.29 | 61.29 | 518.43 | 531.65 | 0.6585 | 1.27 | 6.04 | 34,437,900.00 | 7.79 | 9.24 | 11.08 | 13.43 | 58.76 | 53.30 | 11.83 | 12.72 | 1.10 | 13.69 | 0.2144 | 8.64 | 16.68 | 8.19 | 64.62 | 6.06 | 17.96 | 12.47 |
| Lupin Ltd | 214.31bn | 26.26bn | 953.49bn | 21.87k | 36.40 | 6.10 | 25.98 | 4.45 | 57.42 | 57.42 | 468.54 | 342.91 | 0.8761 | 1.35 | 4.48 | 9,800,284.00 | 10.84 | 1.43 | 16.64 | 2.22 | 68.60 | 58.52 | 12.37 | 2.04 | 1.22 | 11.88 | 0.1797 | 75.03 | 20.25 | 6.41 | 345.15 | 30.18 | -1.17 | 9.86 |
| Zydus Lifesciences Ltd | 214.84bn | 42.78bn | 955.67bn | 26.24k | 22.39 | 4.38 | 18.56 | 4.45 | 42.41 | 42.66 | 212.94 | 216.89 | 0.7495 | 1.75 | 5.01 | 8,187,310.00 | 15.00 | 9.05 | 19.96 | 14.01 | 71.43 | 61.15 | 20.01 | 14.33 | 1.58 | 217.94 | 0.0078 | 16.48 | 13.40 | 8.23 | 95.25 | 15.72 | -3.03 | -3.04 |
| Mankind Pharma Ltd | 110.18bn | 21.15bn | 1.05tn | 19.54k | 49.75 | 9.94 | 40.94 | 9.53 | 52.70 | 52.70 | 274.57 | 263.69 | 0.8786 | 2.02 | 9.46 | 5,638,684.00 | 17.05 | -- | 21.79 | -- | 70.48 | -- | 19.41 | -- | 2.37 | 99.72 | 0.0428 | -- | 18.12 | -- | 49.23 | -- | -- | -- |
| Dr Reddy's Laboratories Ltd | 300.85bn | 53.39bn | 1.05tn | 26.34k | 19.74 | 3.42 | 15.16 | 3.50 | 64.03 | 64.03 | 360.85 | 369.12 | 0.7379 | 1.37 | 3.90 | 11,420,450.00 | 13.31 | 11.37 | 18.14 | 16.02 | 70.69 | 65.86 | 18.03 | 14.63 | 1.36 | 30.69 | 0.1349 | 15.91 | 13.54 | 12.64 | 23.75 | 23.39 | 26.78 | 14.87 |
| Torrent Pharmaceuticals Ltd | 112.25bn | 18.02bn | 1.07tn | 14.92k | 59.17 | 14.21 | 41.01 | 9.50 | 53.25 | 53.25 | 331.63 | 221.72 | 0.7525 | 1.22 | 6.35 | 7,525,369.00 | 12.08 | 8.34 | 17.95 | 13.03 | 75.52 | 71.78 | 16.06 | 13.18 | 0.7444 | 9.32 | 0.2941 | 61.65 | 11.51 | 6.93 | 33.02 | 30.58 | -8.17 | 26.93 |
| Cipla Ltd | 265.12bn | 44.75bn | 1.23tn | 27.76k | 27.53 | 4.34 | 22.29 | 4.65 | 55.39 | 55.39 | 328.19 | 351.20 | 0.803 | 1.58 | 5.08 | 9,549,060.00 | 13.58 | 10.09 | 16.44 | 12.40 | 67.01 | 58.63 | 16.92 | 12.66 | 2.82 | 69.41 | 0.016 | 21.39 | 13.28 | 9.51 | 47.10 | 21.96 | 20.68 | 34.08 |
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 08 Aug 2024 | 31.77m | 3.16% |
| ICICI Prudential Asset Management Co. Ltd.as of 31 Oct 2024 | 16.66m | 1.66% |
| Kotak Mahindra Asset Management Co. Ltd.as of 30 Sep 2024 | 15.09m | 1.50% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 9.26m | 0.92% |
| PPFAS Asset Management Private Ltd.as of 30 Sep 2024 | 8.15m | 0.81% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 6.07m | 0.60% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Oct 2024 | 4.64m | 0.46% |
| Axis Asset Management Co. Ltd.as of 30 Sep 2024 | 4.40m | 0.44% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 4.36m | 0.43% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Oct 2024 | 3.33m | 0.33% |
